Advertisement

Topics

BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

07:30 EDT 30 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymp...

Other Sources for this Article

Pfizer Inc.
Media:
Sally Beatty (U.S.), 212-733-6566
Lisa O’Neill (Europe), +44 1737 331536
or
Investors:
Ryan Crowe, 212-733-8160

NEXT ARTICLE

More From BioPortfolio on "BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...